Baudax Bio, Inc. (BXRXQ)

Market Cap	52.00
Revenue (ttm)	1.27M +217.3%
Net Income	-7.61M
EPS	-1.91
Shares Out	52.46M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	248,246
Open	0.000001
Previous Close	n/a
Day's Range	0.000001 - 0.0001
52-Week Range	0.000001 - 0.0001
Beta	-27.18
Analysts	n/a
Price Target	n/a
Earnings Date	n/a

About Baudax Bio

Baudax Bio, Inc., a biotechnology company, develops and commercializes products for hospital and other acute care related settings. The company develops T cell receptor, that focus on immune modulating therapies for orphan diseases or complications associated with such diseases, as well as the treatment of autoimmune disorders. It also develops BX1000, an intermediate-acting neuromuscular blocking agent (NMB) that is in phase II clinical trial; BX2000, an ultra- short acting NMB, which is in phase I clinical trial, as well as a proprietary bloc...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2015
• Employees: 9
• Stock Exchange: OTCMKTS
• Ticker Symbol: BXRXQ

Data Source: S&P Global Market Intelligence

Fundamental and historical data is provided by S&P Global Market Intelligence.

Last checked:

Oct 10, 2026

Data Sources Report a data error